Prevention of blindness by screening for diabetic retinopathy

A quantitative assessment

Thomas E. Rohan, C. D. Frost, N. J. Wald

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Diabetic retinopathy is an important cause of blindness in the Western World. A review of the randomised trials of laser photocoagulation of the retina as a method of preventing blindness from this disorder showed that this treatment is very effective, reducing the risk of blindness by 61% in a treated eye. As only one eye is needed for sight the reduction in blindness in a population will be greater than 61% because the effect of treatment in one eye is not always identical with the effect in the other eye. For analysis this reduction was taken as 73%, representing the average of the minimum and maximum estimates (61% and 85%). The effectiveness of this treatment suggests that there is the potential for a national screening programme to bring about a major reduction in blindness from this cause. A quantitative assessment of the effect of screening indicated that a programme in which patients with diabetes mellitus are systematically referred to ophthalmic opticians for a retinal examination could detect 88% of all diabetics with serious retinopathy and that 87% of these cases would be treatable. Screening and early treatment of retinopathy would prevent deterioration of visual acuity and could reduce the risk of blindness due to diabetic retinopathy by an estimated 56% (0.73 x 0.88 x 0.87). The findings suggest that an effectively managed community based screening programme encompassing detection, referral, treatment, and follow up would prevent about 260 new cases of blindness in diabetics under the age of 70 each year in England and Wales. This would represent over 10% of all cases of blindness in adults in this age group.

Original languageEnglish (US)
Pages (from-to)1198-1201
Number of pages4
JournalBritish Medical Journal
Volume299
Issue number6709
StatePublished - 1989
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Blindness
Western World
Light Coagulation
Wales
Therapeutics
England
Visual Acuity
Retina
Diabetes Mellitus
Lasers
Referral and Consultation
Age Groups
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prevention of blindness by screening for diabetic retinopathy : A quantitative assessment. / Rohan, Thomas E.; Frost, C. D.; Wald, N. J.

In: British Medical Journal, Vol. 299, No. 6709, 1989, p. 1198-1201.

Research output: Contribution to journalArticle

@article{fecc5e27cbcc4f1aae91618ea4b4dbf4,
title = "Prevention of blindness by screening for diabetic retinopathy: A quantitative assessment",
abstract = "Diabetic retinopathy is an important cause of blindness in the Western World. A review of the randomised trials of laser photocoagulation of the retina as a method of preventing blindness from this disorder showed that this treatment is very effective, reducing the risk of blindness by 61{\%} in a treated eye. As only one eye is needed for sight the reduction in blindness in a population will be greater than 61{\%} because the effect of treatment in one eye is not always identical with the effect in the other eye. For analysis this reduction was taken as 73{\%}, representing the average of the minimum and maximum estimates (61{\%} and 85{\%}). The effectiveness of this treatment suggests that there is the potential for a national screening programme to bring about a major reduction in blindness from this cause. A quantitative assessment of the effect of screening indicated that a programme in which patients with diabetes mellitus are systematically referred to ophthalmic opticians for a retinal examination could detect 88{\%} of all diabetics with serious retinopathy and that 87{\%} of these cases would be treatable. Screening and early treatment of retinopathy would prevent deterioration of visual acuity and could reduce the risk of blindness due to diabetic retinopathy by an estimated 56{\%} (0.73 x 0.88 x 0.87). The findings suggest that an effectively managed community based screening programme encompassing detection, referral, treatment, and follow up would prevent about 260 new cases of blindness in diabetics under the age of 70 each year in England and Wales. This would represent over 10{\%} of all cases of blindness in adults in this age group.",
author = "Rohan, {Thomas E.} and Frost, {C. D.} and Wald, {N. J.}",
year = "1989",
language = "English (US)",
volume = "299",
pages = "1198--1201",
journal = "BMJ (Online)",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "6709",

}

TY - JOUR

T1 - Prevention of blindness by screening for diabetic retinopathy

T2 - A quantitative assessment

AU - Rohan, Thomas E.

AU - Frost, C. D.

AU - Wald, N. J.

PY - 1989

Y1 - 1989

N2 - Diabetic retinopathy is an important cause of blindness in the Western World. A review of the randomised trials of laser photocoagulation of the retina as a method of preventing blindness from this disorder showed that this treatment is very effective, reducing the risk of blindness by 61% in a treated eye. As only one eye is needed for sight the reduction in blindness in a population will be greater than 61% because the effect of treatment in one eye is not always identical with the effect in the other eye. For analysis this reduction was taken as 73%, representing the average of the minimum and maximum estimates (61% and 85%). The effectiveness of this treatment suggests that there is the potential for a national screening programme to bring about a major reduction in blindness from this cause. A quantitative assessment of the effect of screening indicated that a programme in which patients with diabetes mellitus are systematically referred to ophthalmic opticians for a retinal examination could detect 88% of all diabetics with serious retinopathy and that 87% of these cases would be treatable. Screening and early treatment of retinopathy would prevent deterioration of visual acuity and could reduce the risk of blindness due to diabetic retinopathy by an estimated 56% (0.73 x 0.88 x 0.87). The findings suggest that an effectively managed community based screening programme encompassing detection, referral, treatment, and follow up would prevent about 260 new cases of blindness in diabetics under the age of 70 each year in England and Wales. This would represent over 10% of all cases of blindness in adults in this age group.

AB - Diabetic retinopathy is an important cause of blindness in the Western World. A review of the randomised trials of laser photocoagulation of the retina as a method of preventing blindness from this disorder showed that this treatment is very effective, reducing the risk of blindness by 61% in a treated eye. As only one eye is needed for sight the reduction in blindness in a population will be greater than 61% because the effect of treatment in one eye is not always identical with the effect in the other eye. For analysis this reduction was taken as 73%, representing the average of the minimum and maximum estimates (61% and 85%). The effectiveness of this treatment suggests that there is the potential for a national screening programme to bring about a major reduction in blindness from this cause. A quantitative assessment of the effect of screening indicated that a programme in which patients with diabetes mellitus are systematically referred to ophthalmic opticians for a retinal examination could detect 88% of all diabetics with serious retinopathy and that 87% of these cases would be treatable. Screening and early treatment of retinopathy would prevent deterioration of visual acuity and could reduce the risk of blindness due to diabetic retinopathy by an estimated 56% (0.73 x 0.88 x 0.87). The findings suggest that an effectively managed community based screening programme encompassing detection, referral, treatment, and follow up would prevent about 260 new cases of blindness in diabetics under the age of 70 each year in England and Wales. This would represent over 10% of all cases of blindness in adults in this age group.

UR - http://www.scopus.com/inward/record.url?scp=0024453059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024453059&partnerID=8YFLogxK

M3 - Article

VL - 299

SP - 1198

EP - 1201

JO - BMJ (Online)

JF - BMJ (Online)

SN - 0959-8146

IS - 6709

ER -